HC Wainwright Cuts OnKure Therapeutics (NASDAQ:OKUR) Price Target to $34.00

OnKure Therapeutics (NASDAQ:OKUR - Free Report) had its price objective cut by HC Wainwright from $40.00 to $34.00 in a report released on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for OnKure Therapeutics' Q1 2025 earnings at ($1.41) EPS, Q2 2025 earnings at ($1.43) EPS, Q3 2025 earnings at ($1.27) EPS, Q4 2025 earnings at ($1.15) EPS and FY2025 earnings at ($5.20) EPS.

Several other brokerages have also recently issued reports on OKUR. Leerink Partnrs raised OnKure Therapeutics to a "strong-buy" rating in a report on Thursday, December 5th. Leerink Partners began coverage on OnKure Therapeutics in a report on Thursday, December 5th. They issued an "outperform" rating and a $33.00 target price on the stock. Finally, Oppenheimer reduced their price objective on OnKure Therapeutics from $35.00 to $30.00 and set an "outperform" rating on the stock in a research note on Tuesday, March 11th. Three analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, OnKure Therapeutics presently has a consensus rating of "Buy" and an average price target of $32.33.

OnKure Therapeutics Stock Up 1.0 %

Shares of OKUR stock traded up $0.05 during trading hours on Tuesday, hitting $5.05. The stock had a trading volume of 19,042 shares, compared to its average volume of 85,453. OnKure Therapeutics has a one year low of $4.45 and a one year high of $20.00. The business has a 50-day simple moving average of $5.44. The stock has a market capitalization of $67.85 million, a PE ratio of -0.41 and a beta of 0.28.

Remove Ads

OnKure Therapeutics (NASDAQ:OKUR - Get Free Report) last issued its earnings results on Monday, March 10th. The company reported ($1.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.51). As a group, analysts forecast that OnKure Therapeutics will post -4.05 EPS for the current year.

Institutional Investors Weigh In On OnKure Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Acorn Capital Advisors LLC bought a new stake in OnKure Therapeutics during the fourth quarter worth approximately $12,381,000. Citadel Advisors LLC bought a new position in shares of OnKure Therapeutics during the fourth quarter valued at approximately $8,782,000. Samsara BioCapital LLC bought a new position in shares of OnKure Therapeutics during the fourth quarter valued at approximately $7,088,000. Vestal Point Capital LP bought a new position in shares of OnKure Therapeutics during the fourth quarter valued at approximately $5,461,000. Finally, Deep Track Capital LP bought a new position in shares of OnKure Therapeutics during the fourth quarter valued at approximately $4,506,000. 90.98% of the stock is owned by institutional investors.

About OnKure Therapeutics

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.